Inventor · disambiguated record
Kenjirou Minomi
Also filed as: MINOMI KENJIROU
17 granted patents·8 pending applications·66 citations·filing 2015–2024
93Inventor score
Files withNITTO DENKO CORP25
Top patents by PatentIndex Score
25 records- 0195US9771582B2RNA interference compositions and methods for malignant tumorsNITTO DENKO CORP·Filed 2015·Granted Sep 26, 2017·13 cites·35 claims
- 0293US10047111B2RNA interference agents for GST-PI gene modulationNITTO DENKO CORP·Filed 2015·Granted Aug 14, 2018·11 cites·23 claims
- 0392USRE48887ERNA interference compositions and methods for malignant tumorsNITTO DENKO CORP·Filed 2019·Granted Jan 11, 2022·2 cites·35 claims
- 0492US10047110B2RNA agents for GST-Pi gene modulationNITTO DENKO CORP·Filed 2015·Granted Aug 14, 2018·8 cites·10 claims
- 0592US10023597B2RNA interference agents for p21 gene modulationNITTO DENKO CORP·Filed 2017·Granted Jul 17, 2018·6 cites·9 claims
- 0692US9580710B2Methods and compositions for treating malignant tumors associated with KRAS mutationNITTO DENKO CORP·Filed 2015·Granted Feb 28, 2017·7 cites·27 claims
- 0791US11926831B2SiRNA structures for high activity and reduced off targetNITTO DENKO CORP·Filed 2022·Granted Mar 12, 2024·1 cites·18 claims
- 0891US9695206B2RNA interference agents for P21 gene modulationNITTO DENKO CORP·Filed 2015·Granted Jul 4, 2017·6 cites·8 claims
- 0989US11390871B2SiRNA structures for high activity and reduced off targetNITTO DENKO CORP·Filed 2019·Granted Jul 19, 2022·3 cites·22 claims
- 1087US10358647B2siRNA structures for high activity and reduced off targetNITTO DENKO CORP·Filed 2016·Granted Jul 23, 2019·6 cites·21 claims
- 1186US10792299B2Methods and compositions for treating malignant tumors associated with kras mutationNITTO DENKO CORP·Filed 2017·Granted Oct 6, 2020·3 cites·19 claims
- 1285US2024425862A1Sirna structures for high activity and reduced off targetNITTO DENKO CORP·Filed 2024·Application pending·0 cites
- 1380US2022087531A1Rna interference compositions and methods for malignant tumorsNITTO DENKO CORP·Filed 2021·Application pending·0 cites
- 1476USRE49431ERNA interference agents for GST-PI gene modulationNITTO DENKO CORP·Filed 2020·Granted Feb 28, 2023·0 cites·23 claims
- 1574USRE49229EMethods and compositions for treating malignant tumors associated with KRAS mutationNITTO DENKO CORP·Filed 2020·Granted Oct 4, 2022·0 cites·27 claims
- 1666US11352628B2Methods and compositions for treating malignant tumors associated with KRAS mutationNITTO DENKO CORP·Filed 2019·Granted Jun 7, 2022·0 cites·20 claims
- 1765US10405749B2RNA agents for P21 gene modulationNITTO DENKO CORP·Filed 2015·Granted Sep 10, 2019·0 cites·9 claims
- 1863US2017218365A1Methods for malignant tumors with rnai molecules targeted to hsp47NITTO DENKO CORP·Filed 2017·Application pending·0 cites
- 1960US2022275373A1Methods and compositions for treating malignant tumors associated with kras mutationNITTO DENKO CORP·Filed 2022·Application pending·0 cites
- 2059US2022047619A1Rna interference agents for gst-pi gene modulationNITTO DENKO CORP·Filed 2021·Application pending·0 cites
- 2157US11045488B2RNA interference agents for GST-π gene modulationNITTO DENKO CORP·Filed 2018·Granted Jun 29, 2021·0 cites·21 claims
- 2256US2018002702A1Methods and compositions for treating malignant tumors associated with kras mutationNITTO DENKO CORP·Filed 2017·Application pending·0 cites
- 2350US10780107B2Agent for inducing cell death, agent for suppressing cell proliferation, and pharmaceutical composition used for treatment of disease resulting from abnormal cell proliferationNITTO DENKO CORP·Filed 2017·Granted Sep 22, 2020·0 cites·13 claims
- 2443US2016202242A1Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growthNITTO DENKO CORP·Filed 2015·Application pending·0 cites
- 2536US2016187319A1Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growthNITTO DENKO CORP·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →